A subscription to JoVE is required to view this content. Sign in or start your free trial.

Method Article

Measuring Real-time Drug Response in Organotypic Tumor Tissue Slices

11.5K views

⸱

DOI:

10.3791/61036

⸱

May 2nd, 2020

 ,  , 

In This Article

Summary

We introduce a protocol for measuring real-time drug response in organotypic tumor tissue slices. The experimental strategy outlined here provides a platform to carry out medium-high throughput drug screens on tissue slices derived from clinical or mouse tumors in ex vivo conditions.

Abstract

Tumor tissues are composed of cancerous cells, infiltrated immune cells, endothelial cells, fibroblasts, and extracellular matrix. This complex milieu constitutes the tumor microenvironment (TME) and can modulate response to therapy in vivo or drug response ex vivo. Conventional cancer drug discovery screens are carried out on cells cultured in a monolayer, a system critically lacking the influence of TME. Thus, experimental systems that integrate sensitive and high-throughput assays with physiological TME will strengthen the preclinical drug discovery process. Here, we introduce ex vivo tumor tissue slice culture as a platform for medium-high-throughput drug screening. Organotypic tissue slice culture constitutes precisely-cut, thin tumor sections that are maintained with the support of a porous membrane in a liquid-air interface. In this protocol, we describe the preparation and maintenance of tissue slices prepared from mouse tumors and tumors from patient-derived xenograft (PDX) models. To assess changes in tissue viability in response to drug treatment, we leveraged a biocompatible luminescence-based viability assay that enables real-time, rapid, and sensitive measurement of viable cells in the tissue. Using this platform, we evaluated dose-dependent responses of tissue slices to the multi-kinase inhibitor, staurosporine, and cytotoxic agent, doxorubicin. Further, we demonstrate the application of tissue slices for ex vivo pharmacology by screening 17 clinical and preclinical drugs on tissue slices prepared from a single PDX tumor. Our physiologically-relevant, highly-sensitive, and robust ex vivo screening platform will greatly strengthen preclinical oncology drug discovery and treatment decision making. 

Introduction

Cancer cell interactions with the physical and biochemical properties of the surrounding stromal tissue forms the TME. TME can stimulate tumor growth, metastasis, and modulate tumor response to therapy1. In conventional preclinical drug development, drug candidates are typically first screened using cultured cancer cell lines, an assay platform that critically lacks the TME2. This lack of physiological TME in cell-based prescreening stages may limit the discovery of effective agents in tumor-bearing animal models and may contribute to the high attrition rate of many promising oncology drugs in later clinical stages of de....

Access restricted. Please log in or start a trial to view this content.

Protocol

All mouse experiments were performed according to the recommendations in the Guide for the Care and Use of Laboratory Animals of the Animal Welfare Act and the National Institutes of Health guidelines for the care and use of animals in biomedical research.

1. Preparation of tumor tissue slices

  1. Prepare tissue slice culture (TSC) medium following the recipe in Table 1. Filter the medium with a 0.45 µm vacuum filter unit to sterilize.
  2. Aliquot 250 µL of TSC medium per well for a 24 well plate, or 1 mL of medium per well for a 6 well plate. Keep the plate in a 37 °C, 5% CO2 humidified incubator u....

Access restricted. Please log in or start a trial to view this content.

Results

Here, we demonstrate a time-course, multiple drug efficacy evaluation protocol for tumor tissue slices prepared from mouse 4T1 breast tumor tissues and a breast cancer PDX model, HCI01012. We successfully prepared tissue slices from several mouse-derived tumors, PDX, and fresh patient tumors10. The overall workflow of the tumor tissue preparation and drug efficacy test is described in Figure 1. In general, we could prepare 20–40 tissue slices f.......

Access restricted. Please log in or start a trial to view this content.

Discussion

In this protocol, we demonstrate a platform for quantitative, and real-time drug efficacy studies on organotypic tumor tissue slices. The tissue slice culture system provides distinct advantages over traditional cell-based in vitro methods by capturing cell heterogeneity and physiological characteristics of the native tumor microenvironment. This platform also enables higher throughput for drug efficacy testing, helping to bridge the gap between cell culture studies and in vivo experiments.

To.......

Access restricted. Please log in or start a trial to view this content.

Disclosures

The authors have nothing to disclose.

Acknowledgements

This work was supported by the NIH/NCI [K22CA201229, P30CA015704], and Sidney Kimmel Foundation [Kimmel Scholar Award], Lung Cancer Discovery Award (LCD-505536). We would like to thank Dr. Alana Welm (University of Utah) for providing the breast cancer PDX tumor. We would also like to thank the staff at Comparative Medicine, Fred Hutchinson Cancer Research Center (FHCRC) for maintenance of the PDX model and members of the Gujral lab for helpful discussions. N.N.A is supported by the JSPS Overseas Research Fellowship and Interdisciplinary Training Grant from FHCRC. A.J.B. is supported by the Chromosome Metabolism and Cancer Training Grant from FHCRC.

....

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
10 cm dishCorning430293
24-well dishCytoOneCC7682-7524
4T1ATCCCRL-2539
6 mm diameter Biopsy punchIntegra Miltex33-36
6-well plateCytoOneCC7682-7506
Ascorbic AcidSigma-AldrichA8960-5gFor TSC medium
Belzer UW cold storage solcution (UW solution)Bridge to Life500 mL
Corning Matrigel Membrane MixFisher scientific356234
DMSOCorningMT-25950CQC
Double Edge Stainless Steel Cutting BladesTED PELLA121-6For slicing
Doxorubicin (hydrochloride)Cayman Chemical15007
FBSGibco26140-079
Fine tip forcepsROBOZRS-4974
Fine tip forcepsROBOZRS-4976
GlucoseSigma-AldrichG5767-500gFor TSC medium
HBSS without Calcium, Magnesium or Phenol RedGibco14-175-103
HCI010Dr. Alana Welm, University of UtahBreast cancer PDX
HEPES Buffer SolutionGibco15630080For TSC medium
ITS + PremixFisher Scientific354352For TSC medium
IVIS SpectrumPerkinElmer124262
Leica VT1200S VibratomeLeicaVT1200S
L-GlutamineGibco25030164For TSC medium
Millicell Cell Culture Insert, 12 mm, hydrophilic PTFE, 0.4 µmMilliporePICM01250
Millicell Cell Culture Insert, 30 mm, hydrophilic PTFE, 0.4 µmMilliporePICM03050
NicotinamideSigma-AldrichN0636-500gFor TSC medium
PELCO Pro CA44 Tissue AdhesiveTED PELLA10033Glue
Pen StrepGibco15140-122
Penicillin-StreptomycinFisher Scientific15140163For TSC medium
RealTime-Glo MT Cell Viability AssayPromegaG9711
Recombinant Mouse EGFBioLegend585608For TSC medium
RPMI1640Gibco11875135
Single Edge Industrial Razor BladesVWR55411-050For removing glued tissues
Sodium BicarbonateCorning25-035-CIFor TSC medium
Sodium PyruvateFisher ScientificBW13115EFor TSC medium
StaurosporineSanta Cruz Biotechnologysc-3510A
Synergy H4BioTek
Tooothed forcepsROBOZRS-5155
Transfer pipettesFisher scientific13-711-7MWide tip
Transfer pipettesSamco Scientific235Fine tip
William's medium E, no glutamineThermoFisher Scientific12551032For TSC medium

References

  1. Klemm, F., Joyce, J. A. Microenvironmental regulation of therapeutic response in cancer. Trends in Cell Biology. 25 (4), 198-213 (2015).
  2. Horvath, P., et al. Screening out irrelevant cell-based models of disease. Nature Reviews: Drug Discovery.

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Explore More Articles

Organotypic CultureReal-time Viability AssayDrug Screening PlatformVibratome SectioningLuminescence-based MeasurementPatient-derived XenograftDose-dependent ResponseMedium-throughput ScreeningTumor Microenvironment